Kairasec Tafla 32 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

kairasec tafla 32 mg

medical valley invest ab - candesartanum cílexetíl - tafla - 32 mg

Oracea Hart hylki með breyttan losunarhraða 40 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

oracea hart hylki með breyttan losunarhraða 40 mg

galderma nordic ab - doxycyclinum inn - hart hylki með breyttan losunarhraða - 40 mg

Sativex Munnholsúði, lausn 27 mg/ml + 25 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sativex munnholsúði, lausn 27 mg/ml + 25 mg/ml

jazz pharmaceuticals ireland ltd - delta-9-tetrahydrocannabinolum; cannabidiolum inn - munnholsúði, lausn - 27 mg/ml + 25 mg/ml

Valsartan Jubilant Filmuhúðuð tafla 160 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

valsartan jubilant filmuhúðuð tafla 160 mg

jubilant pharmaceuticals nv - valsartanum inn - filmuhúðuð tafla - 160 mg

Ebglyss Evrópusambandið - íslenska - EMA (European Medicines Agency)

ebglyss

almirall, s.a. - lebrikizumab - dermatitis, atópísk - aðrar húðsjúkdómar - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.